BRCA2 and Familial prostate cancer: Compared with wild-type (WT) tumors, significantly more adaptive immune response cells, especially tumor-infiltrating lymphocytes (TILs), are enriched in BRCA1/2 mutant TNBC, as well as prostate cancer and pancreatic cancer with BRCA2, PALB2, or ATM germline mutations.